Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
Date:2/4/2008

www.simcere.com" target="_new">http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti- stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
2. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
3. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
4. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
5. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
6. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
9. Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year
10. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
11. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... Sanger Institute announce the first comprehensive analyses of cancer ... in the DNA of cancer cells which are acquired ... melanoma and a lung cancer, reveal for the first ... two cancers. , Lung cancer causes around one million ... smoking. The number of mutations found suggest that a ...
(Date:12/16/2009)... Cost-Effective Care , ... Washington, D.C. (Vocus) December 16, ... ways to rein in runaway costs while providing care to all ... the ongoing discussion includes how to ensure patients equal access to ... (MDs) or osteopathy (DOs). In both the House and Senate ...
(Date:12/16/2009)... Massachusetts companies through annual marketing campaign , ... ... unveiled the 2010 Genetown™ Hotbed Campaign as its ... ,Genetown is sponsored by MassBio and showcases 37 ... campaign places each entity’s brand on an electronic and ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Thriving Bioscience Region Leaves Its Mark 2
... has concluded that several young men treat their erection ... doctors prescription. // These results were revealed after an ... Chicago universities. ,The research was led by ... Chicago and their results were presented in San Francisco, ...
... Saturday that she would lift her surveillance zone for wild ... dead swan// was found to have the lethal H5N1 strain ... stopping the spread of the deadly bird flu virus in ... were imposed after finding the highly pathogenic H5N1 virus in ...
... a precautionary measure and action against smoking in Scotland, it would ... be permitted to buy it. ,Ministers have not decided ... so, given Jack McConnell's determination to reduce smoking rates in Scotland. ... of Ash Scotland and a member of the expert group, "Smoking ...
... Service for Wales published, figures for rates of serious ... is taken to assure// the public that all measures ... the public. John Wardell, 76, a former theatre ... at Abergele Hospital in 2003. It is resistant to ...
... A new study published in the May issue of The ... important role in males as well. Low levels of the ... men, the study found. Those who had low levels of ... ,The study was conducted by Shreyasee Amin, M.D., Mayo Clinic ...
... records will now be open to checking by health workers, who ... the records to verify if patients// have undergone the required ... high BP. This is a move by the Scottish government to ... will certainly give the doctors a clear picture of the patient ...
Other Medicine News:Health News:Young Men Treating Erection Problems without Doctors Prescription 2Health News:Hip Fracture Risk Increases In Men Having Low Estrogen Levels 2
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ... recently closed a bridge loan financing (the "2009 ... Purchase Agreement (the "Agreement") with Firebird Global Master ... Company sold a convertible promissory note, due June ... US$1,400,000, and issued a warrant to purchase an ...
(Date:12/16/2009)... 16 International, well-known,scientific experts ... GFT505 (80 mg/day),data presented as "extremely ... scientists and clinicians critically reviewed these ... of generic lipid-modifying,treatments, fenofibrate and bezafibrate, ... observed in patients with metabolic syndrome,and ...
(Date:12/16/2009)... Boston Scientific Corporation (NYSE: BSX ... has elected Nelda Connors as a Director. ... and Metal Products division of Tyco International. Previously, ... several positions in operations and general management. Prior ... of executive and management capacities with Ford, Chrysler and ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 1Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 2Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 3Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 4Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 5IgeaCare Solutions Inc Emerges Under New Leadership and Funding 11022 1IgeaCare Solutions Inc Emerges Under New Leadership and Funding 11022 2New approach to sickle cell disease shows promise in mice 62780 1New approach to sickle cell disease shows promise in mice 62780 2
... -, BRIDGEWATER, N.J., Sept. 18 Results ... study showed that 84 percent of,treatment-naive HIV-1 infected ... mg (two 400 mg tablets) with 100 mg ... reached an undetectable viral load (<50 copies/mL) at ...
... FOLD ) today announced that it plans to ... HCl) for Pompe Disease at the,American Society of Human ... CA. This plan was announced by John Crowley, President ... & Medtech 2007 Conference in London, United Kingdom. ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease 2
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
Total T3 EIA Thyroid Function 025-BC-1005...
... anti-TPO test kit is a solid phase ... It is designed for the quantitative measurement ... in serum or plasma. The microplate is ... controls and patient samples are pipetted into ...
Medicine Products: